DP-R212 Pharmacokinetic Study

• Status: Unknown status
• Trial end date: 2016-07-01
• Target enrollment: 0
• Participant gender: Male

Summary

An open-label, multiple-dose study to evaluate the pharmacokinetic drug-drug interaction of amlodipine and rosuvastatin in healthy adult male subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Alvogen Korea
• Treatments: Amlodipine; Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• BMI 18-29

• signed the informed consent form prior to the study participation

Exclusion Criteria:

• Clinically significant disease

• Previously donate whole blood within 60 days or component blood within 14 days

• Clinically significant allergic disease

• Taken IP in other trial within 90 days

• An impossible one who participates in clinical trial by investigator's decision including laboratory test result